The second committee discussion of palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915] will be held on 8 June 2017 at NICE London Offices, Prince of Wales Suite 10 Spring Gardens SW1A 2BU.